ClinicalTrials.gg
RecruitingNCT06448390Updated Jun 6, 2025

Exercise Training Study of Patients With Claudicatio Intermittens

An interventional study of Physical training in Claudication, Intermittent, sponsored by Norwegian University of Science and Technology. Recruiting at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by Norwegian University of Science and Technology · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Jan 2024, registered Jun 2024).
  • Started Jan 2024; still recruiting 2 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to evaluate whether walking capacity in patients with intermittent claudication is improved more by home-based 5+ exercise training than by current recommendations of daily walking.

Read the detailed description

Patients with intermittent claudication will by a web-based program be randomized to either "five plus training" or walking at least 30 minutes three times per week. During the "five plus training" the participants are standing in front of a wall, which is used for support of the balance. The body is lifted with the calf musculature to the maximal height that the subject can achieve. This is repeated until pain is felt in the calf musculature. Following the initiation of pain the subject performs five extra repetitions. The five extra calf raises are included to secure induction of ischemia followed by reperfusion to secure maximal training effect.

The patients are followed by absolute walking distance on a treadmill, quality of life questionnaire, and Ankle-brachial index.

02

Conditions studied

  • Claudication, Intermittent
03

In context

Intermittent Claudication

309 studies on the registry are indexed under Intermittent Claudication; 46 are open to participants now.

This study's planned enrollment of 100 is above the median of 74 across 242 interventional studies indexed under Intermittent Claudication.

Browse Intermittent Claudication studies →

Lead sponsor

Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pain in the calves after 300 m, or less measured on a treadmill
  2. Stable symptoms last 6 months or more
  3. The pain must be gone within 5 minutes after the patients stop walking
  4. Ankle-Brachial index at 0.7 or lower at rest
  5. Using statins and antiplatelet drugs since at least 3 months
  6. age> 18 years
  7. Signed consent

Exclusion criteria

Exclusion Criteria:

  1. pain in the hips or elsewhere outside the calves while walking
  2. Remaining pain more than 5 minutes after stopped walking.
  3. Impossible to compress the arteries while measruing ABI or ABI lower than 0.4
  4. Use of statins and antiplatelet drugs less than 3 months
  5. symptoms less than 6 months
  6. Diabetes measured with being over 48 mmol/mol (6%)
  7. Revascularisation the last 6 months
  8. Pain in the calves after longer than 300 m measured on a treadmill
  9. Reduced mobility in the ankles
  10. Reduced physical ability to perform a test on a treadmill.
  11. Age less than 18 years
  12. General conditions that impairs the ability to take part in a training study including Obesity, KOLS, heart disease, arthrosis, inflammatory joint diseases .
  13. No Signed consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Single group
Masking
Double (Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Five plus training

    During "five plus training" the participants are standing in front of a wall, which is used for support of the balance. The body is lifted with the calf musculature to the maximal height that the subject can achieve. This is repeated until pain is felt in the calf musculature. Following the initiation of pain the subject performs five extra repetitions. The five extra calf raises are included to secure induction of ischemia followed by reperfusion to secure maximal training effect.

    Behavioral: Physical training

  • Active comparator
    walking

    Walking at least 30 minutes three times per week.

    Behavioral: Physical training

Interventions

  • BehavioralPhysical training

    The patients are randomized to either walking 30 minutes 3 times a week or lifting the body to a tip toe position three times a day until pain in the claves and then add another five liftings before ending the session

06

What researchers measure

Primary outcomes

  1. walking distance

    Measured on a tread mill before and after the training period

    Time frame: 12 weeks

  2. Quality of life

    Measured with a questionnaire (VASCUQOL-6) before and after the training period

    Time frame: 12 weeks

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — According to the ethical permission no individual data can be shared or identified. The participant can be fully informed if that is requested

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.

Of 73 non-industry interventional studies with no phase under Intermittent Claudication, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 77. This study's planned 23 months is below that.

Counting every sponsor, half of 84 studies reached it within 41 months; a quarter within 17 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2024
First posted
Jun 7, 2024
StartActual
Jan 1, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jun 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06448390
Collaborators
Sykehuset i Vestfold HF, Oslo University Hospital, Haukeland University Hospital, Sorlandet Hospital HF, St. Olavs Hospital, Sykehuset Ostfold, Helse Stavanger HF, Sykehuset Innlandet HF, Drammen sykehus, Alesund Hospital, Sahlgrenska University Hospital, Karolinska Institutet, University Hospital, Linkoeping
Responsible party
Sponsor
First posted
Jun 7, 2024
Start date
Jan 1, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jun 6, 2025

Study contacts

Erney Mattsson, Professor
Contact
erney.mattsson@gmail.com
0046737854490
Joakim Nordanstig, Professor
Contact
joakim.nordanstig@vgregion.se
+46708259496
Joakim Nordanstig, Professor
principal investigator · Sahlgrenska University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion